Hesam-Shariati, Negin http://orcid.org/0000-0003-0829-7016
Alexander, Lara
Chen, Kevin Yi
Craig, Ashley http://orcid.org/0000-0001-7647-7604
Glare, Paul A.
Jensen, Mark P.
Lin, Chin-Teng
McAuley, James H.
Middleton, James W. http://orcid.org/0000-0002-2777-8619
Moseley, G. Lorimer
Newton-John, Toby
Restrepo, Sebastian
Skinner, Ian W.
Zahara, Pauline
Gustin, Sylvia M.
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (2001653, 2021183)
Rebecca L. Cooper Medical Research Foundation
Article History
Received: 23 April 2024
Revised: 28 August 2024
Accepted: 3 September 2024
First Online: 12 September 2024
Competing interests
: GLM is the non-paid CEO of the non-profit Pain Revolution. He has received speaker fees for lectures on pain, pain education, and rehabilitation. He also receives royalties for books on pain and pain education. Professional and scientific bodies have reimbursed him for travel costs related to presentations at scientific conferences and symposia. The other authors declare no competing interests.
: The StoPain trial is approved by the Human Research Ethics Committee of the University of New South Wales (HC230510), and is registered at Australian New Zealand Clinical Trials Registry (ACTRN12623000846628).